Jun 08, 2023 / 06:30PM GMT
Michael Tung - FibroGen, Inc. - IR
Thank you, everyone, for joining us at our next session. I am very happy to have the CEO of FibroGen up here on the stage with us, CEO Enrique Conterno. It's great to have you here.
Obviously, FibroGen is at an exciting and critical juncture for the company. They have been obviously executing on roxadustat across the commercial business with its partner AstraZeneca in China. And obviously, they have been executing on the pipeline with pamrevlumab, of which there are multiple Phase 3 readouts coming. And one was recently, which we've talked about, but certainly more to come.
So I would love, Enrique, maybe just to make some opening comments about FibroGen with a focus specifically, first on pamrevlumab. I think everybody would love to hear about how you're thinking about the recent news for pamrevlumab this week and obviously, how to think about the upcoming IPF study and the other readouts that are coming for pamrevlumab.
Enrique Conterno - FibroGen, Inc. - CEO
Very good. Now, thank you very much for the
FibroGen Inc at Jefferies Healthcare Conference Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers